AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Left Atrial Biomarker Profiles Differ from Peripheral Venous Biomarkers: The Liraglutide Effect on Atrial Fibrillation (LEAF) Biomarker Study
By Iacobellis G, Mitrani R, Mendez AJ et al.
Background: The left atrium (LA) has bidirectional communication with the LA epicardial adipose tissue (LAEAT) so that LA blood may be enriched by adipokines released by the LAEAT. Research Question: In obese patients with atrial fibrillation (AF), do LA biomarkers differ from peripheral venous biomarker levels. Methods: 59 patients with BMI≥27 kg/m ² who opted for AF ablation were randomized to pre-ablation risk factor modification (RFM) or RFM+Liraglutide. 54 patients had AF ablation (81.5% persistent AF) and LA blood was drawn after transeptal catheterization. Peripheral blood samples were also obtained within 1-2 days prior to ablation. Pre-ablation CT scans assessed LAEAT volume and density (HU); 5 patients were excluded due to technical issues. Biomarkers of inflammation (CRP, galectin, IL-6, MCP-1, TNFα, resistin) and fibrosis (Activin A, TGFß, MMPs, TIMPs) were assayed with commercial kits. P-values were adjusted for multiple comparisons. Results: There were 27 RFM (age 62±10 years, BMI 33.4 [30.4, 38.0] kg/m ² ) and 27 RFM+L (age 63±8 years, BMI 37.1 [32.0, 39.7] kg/m ² ). LA biomarkers did not differ between RFM and RFM+L groups. LA biomarkers differed significantly (p<0.01) from peripheral venous biomarkers for CRP, galectin, Activin A, TGFß, MMPs, and TIMPs. Strong (r>0.55, p<0.0001for CRP , Galectin , IL-6, Resistin, MMP1), moderate (r=0.31-0.43 for MCP-1, TIMP1), and no significant (TNF-α, TGF-β , MMP2 , MMP8 , MMP9 , TIMP2) correlations were noted for LA versus peripheral values. Figure shows a unique bimodal distribution with no overlap between the high (2090.7±386.9 pg/ml) and low (304.0±108.3 pg/ml) LA Activin A level groups- for any given value of peripheral venous Activin A, the LA level could be low or high. The only clinical characteristics that differed between low and high Activin A levels were increased abdominal circumference (p=0.022) and greater ß-blocker use (p=0.004) in the high Activin A group. Weak correlations between LAEAT volume and MMP1 (r=0.28, p=0.049), and between LAEAT HU and MMP1 (r=-0.25, p=0.083), MMP8 (r=-0.30, p=0.053), MMP9 (r=-0.27, p=0.077), TIMP1 (r=-0.37, p=0.015), and TIMP2 (r=-0.27, p=0.076) were noted for LA biomarkers. LAEAT Volume (r=0.35, p=0.009) and HU (r=-0.37, p=0.006) correlated with peripheral MMP1 and weakly with MMP8 (r=0.25, p=0.076; r=-0.25, p=0.070). Conclusion: The local LA biomarker milieu is influenced by the LA (myocardium and/or LAEAT) and is not reliably reflected by measurement of biomarkers from peripheral venous blood for many important biomarkers, including Activin A. As pharmacologic targeting of activin action is on the horizon, assessment of LA Activin A levels could facilitate personalized medicine approaches to AF treatment.